JAMES M. FRATES - 11 Feb 2022 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Chief Financial Officer
Signature
/s/ Joshua B. Cohen, as Attorney in Fact for James Frates
Issuer symbol
AMLX
Transactions as of
11 Feb 2022
Transactions value $
$0
Form type
4
Filing time
28 Mar 2022, 16:30:25 UTC
Previous filing
26 Apr 2023
Next filing
17 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Stock Option (right to buy) Award $0 +25,000 $0 25,000 11 Feb 2022 Common Stock 25,000 $19.62 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4 of the shares subject to the option shall vest and become exercisable on the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date.